SAN DIEGO and SHANGHAI, Sept. 26, 2023 /PRNewswire/ -- ABM Therapeutics is pleased to announce today that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for the investigation of ABM-1310 for the treatment of Glioblastoma (GBM) patients carrying BRAF V600E mutation, following the Orphan Drug Designation for ABM-1310 to treat malignant gliomas including GBM received in July.
ABM Therapeutics, a clinical-stage biopharmaceutical company, announced that the first patient has been successfully dosed in its multicenter phase I study of ABM-1310 in patients with relapsed and drug resistant primary malignant brain tumours in China. This is the second clinical study of ABM-1310 in China.
SAN DIEGO, Calif. and SHANGHAI, Sept. 1, 2023 /PRNewswire/ -- ABM Therapeutics, a clinical-stage biopharmaceutical company, today announced that the first patient has been successfully dosed in its multicenter Phase I study of ABM-1310 in patients with relapsed and drug resistant primary malignant brain tumors in China. This is the second clinical study of ABM-1310 in China.
ABM-168 has good water solubility, high cell permeability and brain penetration properties.
SAN DIEGO and SHANGHAI, May 4, 2023 /PRNewswire/ -- ABM Therapeutics, an innovative clinical-stage biopharmaceutical company, with an emphasis on developing drugs with high blood–brain barrier (BBB) penetration for CNS diseases including brain metastases, today announced that the first patient was successfully dosed with ABM-168 in the United States.
SAN DIEGO and SHANGHAI, Nov. 30, 2021n/PRNewswire/ -- ABM Therapeutics (ABM), a clinical-stage nbiopharmaceutical company with a focus on treating brain cancers and ncancer metastases, today announced that its IND application for nABM-1310, a new-generation BRAF inhibitor, has been approved by the nNational Medical Products Administration (NMPA) to conduct Phase 1 nclinical trials in patients of advanced solid tumors with BRAF mutation nin China. This is the first clinical candidate and IND approval obtained by ABM Therapeutics in China.